NASDAQ:DBVT DBV Technologies (DBVT) Stock Forecast, Price & News $1.44 -0.03 (-2.04%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$1.40▼$1.4650-Day Range$1.40▼$1.7952-Week Range$1.08▼$2.37Volume31,401 shsAverage Volume61,564 shsMarket Capitalization$277.20 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media DBV Technologies MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside386.1% Upside$7.00 Price TargetShort InterestBearish0.61% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$42,540 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.54) to ($0.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.63 out of 5 starsMedical Sector862nd out of 965 stocksBiological Products, Except Diagnostic Industry135th out of 160 stocks 3.3 Analyst's Opinion Consensus RatingDBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, DBV Technologies has a forecasted upside of 386.1% from its current price of $1.44.Amount of Analyst CoverageDBV Technologies has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.61% of the outstanding shares of DBV Technologies have been sold short.Short Interest Ratio / Days to CoverDBV Technologies has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in DBV Technologies has recently increased by 0.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDBV Technologies does not currently pay a dividend.Dividend GrowthDBV Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DBVT. Previous Next 0.0 News and Social Media Coverage MarketBeat FollowsOnly 1 people have added DBV Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DBV Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $42,540.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.71% of the stock of DBV Technologies is held by insiders.Percentage Held by InstitutionsOnly 23.90% of the stock of DBV Technologies is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DBV Technologies are expected to grow in the coming year, from ($0.54) to ($0.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DBV Technologies is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DBV Technologies is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDBV Technologies has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DBV Technologies (NASDAQ:DBVT) StockDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Read More DBVT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DBVT Stock News HeadlinesSeptember 12, 2023 | americanbankingnews.comDBV Technologies (NASDAQ:DBVT) Receives New Coverage from Analysts at StockNews.comSeptember 8, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Lower ThursdaySeptember 22, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 30, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Higher WednesdayAugust 30, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Gaining TuesdayAugust 4, 2023 | benzinga.comDBV Technologies And 3 Other Penny Stocks Insiders Are BuyingAugust 1, 2023 | msn.comDBV Technologies Advances Peanut Allergy Program With FDA Support On Pediatric StudiesAugust 1, 2023 | finance.yahoo.comDBV.PA - DBV Technologies S.A.September 22, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 1, 2023 | markets.businessinsider.comDBV Technologies SA – American (DBVT) Receives a Buy from JMP SecuritiesJuly 31, 2023 | finance.yahoo.comDBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial ResultsJuly 25, 2023 | finance.yahoo.comDBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate UpdateJuly 19, 2023 | finance.yahoo.comMonthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023July 13, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise Sharply ThursdayJune 22, 2023 | uk.finance.yahoo.comDBV.F - DBV Technologies S.A.June 22, 2023 | uk.finance.yahoo.comDBVT - DBV Technologies S.A.June 16, 2023 | finance.yahoo.comMonthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023June 14, 2023 | finance.yahoo.comDBV Technologies S.A. (DBVT) stock forecast and price targetJune 10, 2023 | thestreet.comDBV Technologies CEO: Peanut Allergy Patch Propelling StockJune 8, 2023 | finanznachrichten.deDBV Technologies S.A.: DBV Technologies to Participate in Upcoming EAACI Congress 2023June 8, 2023 | finance.yahoo.comDBV Technologies to Participate in Upcoming EAACI Congress 2023May 12, 2023 | finance.yahoo.comA simple skin patch shows promise for preventing peanut allergiesMay 11, 2023 | marketwatch.comDBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin(TM) Peanut in ToddlersMay 11, 2023 | markets.businessinsider.comGood News For Toddlers With Peanut Allergy: DBVT Data Shows Promising Results for Peanut Allergy PatchMay 11, 2023 | markets.businessinsider.comJMP Securities Sticks to Its Buy Rating for DBV Technologies SA – American (DBVT)May 10, 2023 | finance.yahoo.comDBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in ToddlersMay 9, 2023 | markets.businessinsider.comDBV Technologies SA – American (DBVT) Gets a Buy from H.C. WainwrightSee More Headlines Receive DBVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DBVT Company Calendar Last Earnings7/31/2023Today9/22/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DBVT CUSIPN/A CIK1613780 Webwww.dbv-technologies.com Phone(315) 542-7878Fax33-1-43-26-10-83Employees88Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+386.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,270,000.00 Net MarginsN/A Pretax Margin-1,929.49% Return on Equity-54.06% Return on Assets-42.89% Debt Debt-to-Equity RatioN/A Current Ratio5.86 Quick Ratio5.86 Sales & Book Value Annual Sales$4.84 million Price / Sales57.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.03 per share Price / Book1.40Miscellaneous Outstanding Shares192,500,000Free Float191,135,000Market Cap$277.20 million OptionableOptionable Beta1.17 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Daniel Tassé (Age 63)CEO & Director Comp: $1.21MMr. Sébastien Robitaille (Age 53)Chief Financial Officer Comp: $335.17kDr. Pharis Mohideen (Age 58)Chief Medical Officer Comp: $725.12kMr. Pascal WotlingChief Technical Operations Officer & Chief Quality OfficerMs. Michele F. RobertsonChief Legal OfficerJoseph BeckerVP of Global Corp. CommunicationsMs. Caroline Daniere (Age 48)Chief HR Officer & Chief of Staff Dr. Wence AgbotounouChief Clinical Trial Officer & Sr. VPMr. Edward P. Jordan M.B.A. (Age 55)Sr. VP of Commercial Operations North America Alan KerrSr. VP & Head of Global Regulatory AffairsMore ExecutivesKey CompetitorsScilexNASDAQ:SCLXCompass TherapeuticsNASDAQ:CMPXAcumen PharmaceuticalsNASDAQ:ABOSAlloVirNASDAQ:ALVRMonte Rosa TherapeuticsNASDAQ:GLUEView All CompetitorsInsiders & InstitutionsTimothy E MorrisBought 12,000 shares on 8/25/2023Total: $18,240.00 ($1.52/share)Point72 Asset Management L.P.Bought 3,112,500 shares on 8/15/2023Ownership: 1.617%Citadel Advisors LLCBought 28,901 shares on 8/15/2023Ownership: 0.015%BlackRock Inc.Bought 44,414 shares on 8/11/2023Ownership: 0.529%Optiver Holding B.V.Bought 39,537 shares on 8/10/2023Ownership: 0.021%View All Insider TransactionsView All Institutional Transactions DBVT Stock - Frequently Asked Questions Should I buy or sell DBV Technologies stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DBVT shares. View DBVT analyst ratings or view top-rated stocks. What is DBV Technologies' stock price forecast for 2023? 4 brokerages have issued 1 year price targets for DBV Technologies' shares. Their DBVT share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 386.1% from the stock's current price. View analysts price targets for DBVT or view top-rated stocks among Wall Street analysts. How have DBVT shares performed in 2023? DBV Technologies' stock was trading at $1.53 at the start of the year. Since then, DBVT shares have decreased by 5.9% and is now trading at $1.44. View the best growth stocks for 2023 here. When is DBV Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our DBVT earnings forecast. How were DBV Technologies' earnings last quarter? DBV Technologies S.A. (NASDAQ:DBVT) issued its quarterly earnings results on Monday, July, 31st. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $1 million. What other stocks do shareholders of DBV Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO). What is DBV Technologies' stock symbol? DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT." Who are DBV Technologies' major shareholders? DBV Technologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (1.62%), BlackRock Inc. (0.53%), Optiver Holding B.V. (0.02%), BNP Paribas Arbitrage SNC (0.02%), Citadel Advisors LLC (0.02%) and Envestnet Asset Management Inc. (0.01%). Insiders that own company stock include Daniel B Soland, Pharis Mohideen and Timothy E Morris. View institutional ownership trends. How do I buy shares of DBV Technologies? Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DBV Technologies' stock price today? One share of DBVT stock can currently be purchased for approximately $1.44. How much money does DBV Technologies make? DBV Technologies (NASDAQ:DBVT) has a market capitalization of $277.20 million and generates $4.84 million in revenue each year. The company earns $-96,270,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. How can I contact DBV Technologies? DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The official website for the company is www.dbv-technologies.com. The company can be reached via phone at (315) 542-7878, via email at sara.sherman@dbv-technologies.com, or via fax at 33-1-43-26-10-83. This page (NASDAQ:DBVT) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.